US generics comprise 32% of total revenues. So far, the company has received approval for 165 ANDAs while another 43 are pending approval, of which 24 are Para IV applications. However, Glenmark's derma portfolio is facing stiff pricing pressure in the US. Going ahead, traction from the newly commissioned US based Monroe facility will be the key determinant besides sustained product launches. We expect US to grow at ~5% CAGR in FY1922E to | 3626 crore on the back of new launches. Targeting specific therapies in IPM Glenmark is ranked fourteenth in domestic formulations with a market share...